{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"The Optimism of Bispecific Antibodies","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/d37491f8\"></iframe>","width":"100%","height":180,"duration":1599,"description":"The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic. To date, there have been ten bispecific antibody approvals in oncology, seven of which are for hematological malignancies. Recently, there has been more traction in development pipelines for solid tumors. Most bispecific antibody approvals are currently or projected to be above the $1M annual revenue threshold. Podcast topics include: \t•\tThe biologics of a bispecific antibody\t•\tThe benefits of a bispecific antibody compared to autologous therapies\t•\tThe buzz around Akeso and Summit’s PD-1 VEGF bispecific antibody asset\t•\tThe broad state of bispecifics in approved products and development pipelines\t•\tThe potential of trispecifics, bispecific conjugates and beyond","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}